Vaccine for animal leptospirosis
Polyvalent vaccine (VGNKI) against animal leptospirosis increases immunity by contg. an antigen mixt. of VGNKI-2, -3, -4 and -6 (each of content 10-40%) or a mixt. of VGNKI-1, -4, -5 and -6 (each of content 10-40%). The proposed vaccine contains (per 1 l):leptospira antigens 100-200 mg; Al(OH)3 2.56...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; ita |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Polyvalent vaccine (VGNKI) against animal leptospirosis increases immunity by contg. an antigen mixt. of VGNKI-2, -3, -4 and -6 (each of content 10-40%) or a mixt. of VGNKI-1, -4, -5 and -6 (each of content 10-40%). The proposed vaccine contains (per 1 l):leptospira antigens 100-200 mg; Al(OH)3 2.56-28.9g; serous protein 3.5-7g; preservative 0.1-0.2g; water to 1l. As previously, the vaccine is based on the 6 VGNKI leptospira strains and contains Al(OH)3, preservative, serous protein and water. The proposed method of mer. of the vaccine involves: treating half of the vol. of leptospira culture with trichloroacetic acid (TCAA); pptg. protein and clarifying; decanting 50-70% of the clarified liq. from the acid-treated culture; mixing the remaining part (after its neutralisation) with the sepd. culture. As previously, the process involves cultivation of leptospira strain in serous media, preservation, adding TCAA |
---|